It is RAC. Just to be clear this is not blaming the company but...

It is RAC. Just to be clear this is not blaming the company but the company discussed with clinicians that they would do PET scans before enrolling patients into trials as that was going to help identify the right target patients for their EMD AML trials. While the clinicians gave verbal agreements and the trials were kicked off, even after 6 months we didn’t have a single patient recruited because the clinicians refused to use PET screening without which you couldn’t tell if the patient had EMD form of AML for which the trial was designed. (Obviously @Davisite is the most knowledgeable and can correct me on this.)

I just used this as an example of a risk which I think is “changing user behaviour” be it because of regulatory reasons, hospital guidelines, insurance cover or years of experience using old methods because of which the doctor/ clinician refuse to change their methods or adopt new technologies which could delay adoption of cutting edge science. I am not saying this is a show stopper or the biggest risk or anything; I am just saying this is probably one of the risks for all new technologies or methods which doesn’t get discussed enough. Just because any company may have the latest and the greatest doesn’t mean adoption will skyrocket. We just have to recognise the risk and have temper expectations.

I am still bullish on the company and holding it. No advice. AIMHO only.